Advanz Pharma tipped in the €6.5 million upfront payment for licensing rights.
Have been keeping an eye on their other investments for phase 3 drug 007 from Advanced Theraputics (dated 04.01.23) which announced its phase 3 results on Thursday as follows:
- Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05)
- Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p<0.001)
The only other phase 3 investments from Advanz that I could find, PolyPid, is still recruiting for phase 3 trial.
Advanz Pharma tipped in the €6.5 million upfront payment for...
-
- There are more pages in this discussion • 356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.010(2.56%) |
Mkt cap ! $214.7M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.0¢ | $212.2K | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36350 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 38616 | 11 |
View Market Depth
| Last trade - 13.59pm 13/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |